https://orcid.org/0000-0002-4935-0971
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim
Develop a platform for co-delivering clobetasol propionate (CP) and cyclosporine (CyA) to the epidermis and dermis to treat psoriasis.
Methods
The transfersomes were prepared by thin-film hydration method. Transfersomes were characterised by dynamic light scattering and transmission electron microscope (TEM). Then, the gel stability, viscosity, pH, and spreadability were measured. Cytotoxicity of the CyA-loaded transfersome embedded in CP-dispersed gel (TEG-CyA-CP) was assessed on both human keratinocyte cell line (HaCaT) and Jurkat cells. In vitro cellular uptake and ex vivo dermal distribution was measured. The expression of inflammatory markers was assessed by reverse-transcription PCR (RT-PCR).
Results
Nanoscale (<150 nm) transferosomes with high CyA encapsulation efficiency (>86%) were made. TEG-CyA-CP demonstrated higher viscosity (4808.8 ± 12.01 mPas), which may help control dual drug release. Ex vivo results showed TEG-CyA-CP ability to deliver CyA in the dermis and CP in the epidermis. RT-PCR studies showed the optimised formulation helps reduce the tumour necrosis factor (TNF-α) and interleukin-1 (IL-1) levels to relieve psoriasis symptoms.
Conclusion
The developed TEG-CyA-CP represents a promising fit-to-purpose delivery platform for the dual-site co-delivery of CyA and CP in treating psoriasis.
Acknowledgements
The authors acknowledge the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, for supporting research on cancer and diabetes at NIPER Ahmedabad. RKT would like to acknowledge the Science and Engineering Research Board (Statutory Body Established through an Act of Parliament: SERB Act 2008), Department of Science and Technology, Government of India for the grant (#CRG/2021/005402) and ICMR, NewDelhi for funding the proposal #ID 2021-14161 for work on arthritis in Dr. Tekade’s Laboaratory. RKT would like to acknowledge the Indian Council of Medical Research (ICMR), New Delhi, for the senior research fellowship grants (IRIS Cell No. 2019-4009; File No-5/3/8/33/ITR-F/2018-ITR; File No-5/3/8/53/ITR-F/2020) in Dr. Tekade laboratory.
Disclosure statement
No potential conflict of interest was reported by the authors.